Follow on Google News
News By Tag
* In Vitro
* Rapid Test
* More Tags...
News By Location
Follow on Google News
Hema Diagnostic Systems announces new TYPHOID diagnostic ikn RAPID 1-2-3 EXPRESS format
Hema diagnostic systems announces the availability of a new rapid diagnostic test for typhoid
Typhoid fever is caused by the Gram-negative bacterium known as Salmonella enterica serotype Typhi. The clinical presentation of typhoid fever varies from a mild illness with low-grade fever, malaise, and slight dry cough to a severe clinical picture with abdominal discomfort and multiple complications. Laboratory testing is essential because signs and symptoms may resemble those of other major infectious diseases. The Typhoid F IgM flow assays provide an indirect measure for infection through the detection of pathogen specific antibodies.
“The introduction of the RAPID 1-2-3 HEMA® EXPRESS® TYPHOID comes at a time when world events mandate our increasing attention to those diseases that appear sporadically, and which require an immediate diagnostic response”…according to Lawrence Salvo, President and CEO of Hema Diagnostic Systems. Mr. Salvo went on to say… “by making our Typhoid diagnostic available in the EXPRESS device format, all those in the field who are familiar with the use and application of any other RAPID 1-2-3 HEMA EXPRESS diagnostic will be able to easily and readily administer this rapid test with minimal training.” Concerning the benefits of the diagnostic, Mr. Salvo went on to say: “current fatality rates for those who are positive for Typhoid and who remain untreated, are as high as 10% according the WHO statistics. However, when properly diagnosed and administered the appropriate antibiotic therapy, that number is shown to shrink to 1%. Again, testing can save lives.”
The packaging of the RAPID 1-2-3 HEMA® EXPRESS® TYPHOID is in the same presentation all other EXPRESS devices, and will include both written and pictorial instruction on the back of the foil pouch. With the ability to be stored at room temperature and with the use of whole blood, the RAPID 1-2-3 HEMA® EXPRESS® TYPHOID can easily be transported into almost any emergency diagnostic situation and does not need electricity, special equipment, refrigeration or special training. It is user-friendly and cost-effective. It is designed to meet the needs of those in the field, in a clinic, laboratory or hospital.
About Hema Diagnostic Systems
Hema Diagnostic Systems is HDS is a privately held biotechnology company involved in the development, manufacture, assembly and distribution of diagnostics targeting primary as well as orphan infectious diseases. Incorporating rapid, Point-Of-Care test devices and a new and growing line of ELISA assays, Hema Diagnostic Systems continues to expand its product line to meet the needs of the worldwide market. Point-of-Care test devices are made simple to use and are highly cost effective when incorporated into Hema Diagnostic Systems’ patented delivery systems. The Rapid 1-2-3 Hema EXPRESS as well as the Rapid 1-2-3 Hema EZ® are novel delivery systems that are self contained and easy to use. HDS offers ELISA assays under HDS’ QUANTIFLEXX®
This release may contain forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause actual results to differ, and such differences could be material. Such risks and uncertainties include, but are not limited to, the following: continued acceptance of the Company's products, increased levels of competition in our industry, the acceptance of new products, inherent risks associated with product development and intellectual property rights, the Company’s dependence on key personnel, third party sales and suppliers. There can be no assurance that the Company will be successful in addressing such risks and uncertainties and the Company assumes no duty to update any forward-looking statements based upon actual results.
# # #
Manufacture and distribute rapid diagnostic and elisa tests for infectious duseases around the world. Targeting ngo, fbo and ministries of health throughout africa and south and central america as well as europe.